Let's talk innovation policy.
A New Innovators Group in Geneva
Innovation Council brings a voice of experience from the real economy about the enabling policies that will best support innovation and the diffusion of technology and knowledge over the long-term.
We believe that technological innovation and collaboration among innovators will be critical to achieving the Sustainable Development Goals. We promote inclusive innovation systems, the sharing of know-how on mutually agreed terms, and a fair return for inventive efforts.
Based in Geneva, Switzerland, Innovation Council shares innovators’ perspectives on a range of issues, such as technology diffusion and knowledge-sharing, trade policies, IP protection and enforcement, commercialization of public R&D outcomes, competition rules, open technology standards, and investments in scientific capacity.
Global Innovation Experience
Our members are large and small organizations developing and commercializing new technologies and other solutions that improve people’s lives. We work across sectors and countries, delivering solutions in the form of new medicines, software, seeds, connected devices, processing equipment, materials, and more. Through Innovation Council, our innovators share practical experiences and insights with policymakers in order to contribute to the enactment of enabling policies for innovation and global technology diffusion.Learn More
Innovation Council engages with policymakers and other stakeholders on a range of topics. To learn more about where we stand on these issues, click on the link below.
- Inclusive Innovation Ecosystems
- Policy Discussions and International Organizations
- Innovation and the SDGs
- Enabling Innovation Policies
- Technology and Knowledge Diffusion
‘To be a scientist is a joy’: How a Hungarian biochemist helped revolutionize mRNA
Scientists generally don't seek the limelight, but Dr. Katalin Kariko has been thrust right into it. The once obscure biochemist is now on the....
Australia’s medical innovation approach: Is it suitable for regenerative medicine?
Existing medical innovation pipelines have emerged to support the development of more conventional therapies and are often poorly suited to....
What it would mean for big Pharma if Vaccine IP Rights are waived
With COVID-19 vaccination rollouts in low-income countries still lagging far behind those in rich ones, a group of nations continues to push its....